Remicade® (infliximab): 20 years of contributions to science and medicine

Remicade® (infliximab): 20 years of contributions to science and medicine

Richard Melsheimer,1 Anja Geldhof,1 Isabel Apaolaza,1 Thomas Schaible21Medical Affairs, Janssen Biologics BV, Leiden, the Netherlands; 2Medical Affairs, Janssen Pharmaceuticals, Horsham, PA, USAAbstract: On August 24, 1998, Remicade® (infliximab), the first tumor necrosis factor-α...

Full description

Bibliographic Details
Main Authors: Melsheimer R, Geldhof A, Apaolaza I, Schaible T
Format: Article
Language:English
Published: Dove Medical Press 2019-07-01
Series:Biologics : Targets & Therapy
Subjects:
Remicade (infliximab)
monoclonal antibody
immune-mediated inflammatory disease
TNF inhibition
Crohn’s disease
rheumatoid arthritis
Online Access:https://www.dovepress.com/remicadereg-infliximab-20-years-of-contributions-to-science-and-medici-peer-reviewed-article-BTT

Internet

https://www.dovepress.com/remicadereg-infliximab-20-years-of-contributions-to-science-and-medici-peer-reviewed-article-BTT

Similar Items